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Background
During viral particle production HIV-1 exploits the endo-
plasmic reticulum (ER) to synthesize two factors: Vpu and
gp160. These viral proteins contain a secretion signal and
are thus inserted co-translationally in the ER. The gp160
glycoprotein, undergoes extensive post-translational modi-
fication during its trafficking through the ER. Notably, in
these same compartments also operates the ER-associated
degradation (ERAD) pathway, a quality control mechan-
ism that promotes the proteasomal degradation of mis-
folded proteins that are trafficking through the secretory
pathway.
Since the correct maturation of the gp160 precursor is
absolutely essential to produce infectious viral particles,
we reasoned that inducing the degradation of gp160 in
producing cells may generate an impaired viral progeny.
Materials and methods
We exploited a recently developed technique that allows
the specific degradation of proteins trafficking within
the secretory pathway [1], in this case the precursor
gp160. This method is based on chimeric molecules
named degradins, made of two functional moieties: a
target recognition domain and a degradation-inducing
domain. The latter corresponds to a truncated form of
the ER-resident cellular protein SEL1L which plays a
fundamental role in promoting the entrance into the
ERAD pathway of misfolded proteins. In the present
study we used as target recognition moieties different
single-chain antibodies specific for gp120 and a portion
of the luminal domain of CD4, which is known to bind
gp160 in the ER.
We tested the efficacy of the different degradins both by
co-transfection with gp160 in 293T cells and by measuring
the reduction in the infectivity of vectors produced in
degradin-expressing cells.
Results
By co-expression of gp160 in 293T cells with different
gp160-specific degradins (1339-SEL1L, VRC01-SEL1L,
VRC03-SEL1L, CD4-SEL1L) we obtained decreased cel-
lular levels of gp160. This effect was specific, as demon-
strated by insignificant modulation of gp160 levels by an
irrelevant degradin (1C10-SEL1L), and no downregula-
tion of irrelevant targets (Tetherin, human MHC-I) by
gp160-specifk degradins. In addition, co-expression of
the target recognition moieties contained in gp160-
specific degradins fused to the KDEL ER retention sig-
nal, was unable to lower the intracellular levels of the
viral target.
Finally, we prove that the expression of anti-gp160
degradins in producing cells strongly impairs viral
infectivity.
Conclusions
This study proposes a new strategy to reduce HIV-1
infectivity by interfering with the correct formation of
viral particles. Former approaches obtained reduction of
gp160 incorporation during viral particle assembly
through retention of the gp160 precursor in the ER.
Conversely, the strategy developed in this study is based
on the induction of the active degradation of gp160
through the ERAD pathway during gp160 transition
through the ER.
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